About the President
Dr Alaa Assem is a well rounded professional who had worked in the pharmaceutical industry for over 20 years, in several leading multinational organizations across the Middle East including Sandoz, Lilly, Wyeth, and Pfizer with the last position held was Strategic Public Affairs Director – Middle East. Dr Assem brings to Clinart an extensive and rich experience in managing clinical trials across the region and in accordance with the highest international standards, successfully supporting the registration and pricing of several new innovative products across the Africa and Middle East in different therapeutic areas. Dr Assem is a physician, holding an M.Sc in Ophthalmology from University of Alexandria (Egypt) and an MBA from Maastricht School of Management (Netherlands).
To capture on the continued growth of the CRO market and opportunities in the Africa and Middle East region, Clinart is also pleased to announce that it has attracted an equity investment from Kuwait Life Sciences Company (KLSC) www.klsc.com.kw, an investment company which focuses on healthcare innovative concepts and demanded services that offer significant value to the healthcare sector in Kuwait, Gulf and Middle East. KLSC is fully owned by National Technology Enterprises Company www.ntec.com.kw . KLSC has funded ClinArt to continue its successful growth and expansion all over the Middle East. KLSC has been an active investor internationally and enjoys an extensive network in global healthcare industry.
Dr. Alaa Assem, CEO, Clinart MENA